MedTrace Logo

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

NCT01486940 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 598

Last updated 2017-01-27

No results posted yet for this study

Summary

This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1 diabetes on a basal/bolus regimen.

Conditions

Interventions

DRUG

insulin detemir

Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily

DRUG

insulin aspart

Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals

DRUG

insulin NPH

Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily

DRUG

human soluble insulin

Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2002-10-31
Completion
2002-10-31

Countries

  • Argentina
  • Croatia
  • Czechia
  • Denmark
  • Finland
  • France
  • Greece
  • Italy
  • North Macedonia
  • Norway
  • Poland
  • Romania
  • Russia
  • Slovakia
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01486940 on ClinicalTrials.gov